biotech
AbbVie’s psoriasis drug smashes all endpoints
October 26, 2017Medical Communications, Research and Development AbbVie, IL-23, biotech, drugs, pharma, pharmaceutical, risankizumab
AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat …
GSK eyes healthcare expansion, hits targets due to new drugs
October 26, 2017Sales and Marketing GSK, Merck KGaA, Pfizer, biotech, drugs, healthcare, pharma, pharmaceutical
During the release of Q3 figures, GlaxoSmithKline’s CEO, Emma Walmsley, revealed that the company would consider making moves to bolster …
NHS patients could be offered Airbnb-like accommodation
October 26, 2017Medical Communications NHS, biotech, drugs, pharma, pharmaceutical
In a sign of how desperate the hospital bed situation across the UK is, one council has looked into piloting …
Mental health problems cause 300,000 to leave work each year
October 26, 2017Research and Development biotech, drugs, mental health, pharma, pharmaceutical
A report commissioned by Prime Minister, Theresa May, has found that 300,000 people are leaving their positions of work after …
Lilly looks to leave behind animal health business
October 25, 2017Research and Development, Sales and Marketing Elanco, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Eli Lilly released its Q3 financials and the major talking point was the announcement that the business was reviewing “strategic …
Research finds blood-thinners protect against dementia
October 25, 2017Research and Development Alzheimer's, anticoagulant, biotech, dementia, drugs, pharma, pharmaceutical
Blood-thinning drugs are commonly used to reduce stroke risk in patients with atrial fibrillation (AF) but research from the Karolinska …
Type 3 diabetes more common than Type 1 and often misdiagnosed
October 25, 2017Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
In the first ever study of its kind, researchers from the University of Surrey examined the records of more than …
Novartis Q3: Jimenez talks up Alcon, Gleevec takes generic hammering
October 24, 2017Manufacturing and Production, Sales and Marketing Novartis, biotech, drugs, pharma, pharmaceutical
Novartis released its Q3 financials and, despite Gleevec dipping significantly due to generic competition, still managed to report sales of …
ADC Therapeutics brings in $200 million of financing
October 24, 2017Manufacturing and Production, Sales and Marketing ADC Therapeutics, AstraZeneca, biotech, drugs, pharma, pharmaceutical
ADC Therapeutics has won some serious financial support after its latest financing round managed to net the company $200 million. …
Pharma companies accused of charging NHS twice for treatments
October 23, 2017Medical Communications, Sales and Marketing NHS, biotech, drugs, pharma, pharmaceutical
A new report published by STOP AIDS and Global Justice Now takes aim at three pharmaceutical companies who have taken …
Public Health England sounds warning against overuse of antibiotics
October 23, 2017Medical Communications, Sales and Marketing Antibiotics, biotech, drugs, pharma, pharmaceutical
Public Health England (PHE) has unveiled the findings from its English surveillance programme for antimicrobial utilisation and resistance report, suggesting …
$417 million case against J&J thrown out
October 23, 2017Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, talc
A judge in California has thrown out the lawsuit made by a woman who had alleged that Johnson & Johnson’s …
Report reveals impact of pollution, with 9m deaths worldwide
October 20, 2017Medical Communications biotech, drugs, pharma, pharmaceutical, pollution
A new report published in The Lancet has revealed that all forms of pollution are linked with 9 million deaths …
Small number of mutations driving most cancers
October 20, 2017Medical Communications, Research and Development Cancer, biotech, drugs, pharma, pharmaceutical
Research from scientists at the Wellcome Trust Sanger Institute has found that only between one and 10 genetic mutations are …
Celgene drops $710m drug, shares nosedive 7%
October 20, 2017Medical Communications, Research and Development Celgene, biotech, drugs, pharma, pharmaceutical
Celgene took a gamble when it spent $710 million up-front on an inflammatory disorder treatment, but it now looks likely …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
